APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pertussis Vaccine

Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.

Selected research

Market Outlook & Growth Opportunities

Global Pertussis Vaccine Market Outlook and Growth Opportunities 2026

9 January 2026198 pages

Choose your research edition.

Industry ResearchPertussis Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Pertussis Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Pertussis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pertussis Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pertussis Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.

Global pertussis vaccine key players include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Wuhan Institute of Biological Products, Walvax Biotechnology etc. Global top 2 manufacturers hold a share about 90%. Europe is the largest market, with a share over 30%, followed by North America.

This report provides an overview of the global Pertussis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Pertussis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pertussis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pertussis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pertussis Vaccine Segment by Company

Sanofi Pasteur

GSK

Mitsubishi Tanabe Pharma

Wuhan Institute of Biological Products

Walvax Biotechnology

Minhai Biotechnology

KM Biologics

Chengdu Institute of Biological Products

Pertussis Vaccine Segment by Type

Whole-cell Vaccines

Acellular Vaccines

Pertussis Vaccine Segment by Application

12 Months Below

12 Months Above

Pertussis Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pertussis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pertussis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pertussis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pertussis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pertussis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pertussis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pertussis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pertussis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pertussis Vaccine industry.

Chapter 3: Detailed analysis of Pertussis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pertussis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pertussis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pertussis Vaccine Industry Trends Table 2. Pertussis Vaccine Industry Drivers Table 3. Pertussis Vaccine Industry Opportunities and Challenges Table 4. Pertussis Vaccine Industry Restraints Table 5. Global Pertussis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pertussis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pertussis Vaccine Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Pertussis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pertussis Vaccine Average Price (USD/Doses) of Company (2021-2026) Table 10. Global Pertussis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pertussis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pertussis Vaccine Company, Product Type & Application Table 13. Global Pertussis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pertussis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Whole-cell Vaccines Table 18. Significant Companies of Acellular Vaccines Table 19. Global Pertussis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Pertussis Vaccine Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Pertussis Vaccine Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Pertussis Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Pertussis Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Pertussis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pertussis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pertussis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pertussis Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Pertussis Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of 12 Months Below Table 30. Significant Companies of 12 Months Above Table 31. Global Pertussis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Pertussis Vaccine Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Pertussis Vaccine Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Pertussis Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Pertussis Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Pertussis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pertussis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Pertussis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Pertussis Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Pertussis Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Pertussis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Pertussis Vaccine Sales by Region (2021-2026) & (M Doses) Table 43. Global Pertussis Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Pertussis Vaccine Sales by Region (2027-2032) & (M Doses) Table 45. Global Pertussis Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Pertussis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pertussis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Pertussis Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Pertussis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Pertussis Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Pertussis Vaccine Market Average Price (USD/Doses) by Region (2021-2026) Table 52. Global Pertussis Vaccine Market Average Price (USD/Doses) by Region (2027-2032) Table 53. Global Pertussis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Pertussis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Pertussis Vaccine Sales by Country (2021-2026) & (M Doses) Table 56. Global Pertussis Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Pertussis Vaccine Sales by Country (2027-2032) & (M Doses) Table 58. Global Pertussis Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Pertussis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Pertussis Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Pertussis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Pertussis Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Sanofi Pasteur Company Information Table 64. Sanofi Pasteur Business Overview Table 65. Sanofi Pasteur Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 66. Sanofi Pasteur Pertussis Vaccine Product Portfolio Table 67. Sanofi Pasteur Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 71. GSK Pertussis Vaccine Product Portfolio Table 72. GSK Recent Development Table 73. Mitsubishi Tanabe Pharma Company Information Table 74. Mitsubishi Tanabe Pharma Business Overview Table 75. Mitsubishi Tanabe Pharma Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 76. Mitsubishi Tanabe Pharma Pertussis Vaccine Product Portfolio Table 77. Mitsubishi Tanabe Pharma Recent Development Table 78. Wuhan Institute of Biological Products Company Information Table 79. Wuhan Institute of Biological Products Business Overview Table 80. Wuhan Institute of Biological Products Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 81. Wuhan Institute of Biological Products Pertussis Vaccine Product Portfolio Table 82. Wuhan Institute of Biological Products Recent Development Table 83. Walvax Biotechnology Company Information Table 84. Walvax Biotechnology Business Overview Table 85. Walvax Biotechnology Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 86. Walvax Biotechnology Pertussis Vaccine Product Portfolio Table 87. Walvax Biotechnology Recent Development Table 88. Minhai Biotechnology Company Information Table 89. Minhai Biotechnology Business Overview Table 90. Minhai Biotechnology Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 91. Minhai Biotechnology Pertussis Vaccine Product Portfolio Table 92. Minhai Biotechnology Recent Development Table 93. KM Biologics Company Information Table 94. KM Biologics Business Overview Table 95. KM Biologics Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 96. KM Biologics Pertussis Vaccine Product Portfolio Table 97. KM Biologics Recent Development Table 98. Chengdu Institute of Biological Products Company Information Table 99. Chengdu Institute of Biological Products Business Overview Table 100. Chengdu Institute of Biological Products Pertussis Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 101. Chengdu Institute of Biological Products Pertussis Vaccine Product Portfolio Table 102. Chengdu Institute of Biological Products Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Pertussis Vaccine Distributors List Table 106. Pertussis Vaccine Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Pertussis Vaccine Product Image Figure 2. Global Pertussis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pertussis Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Pertussis Vaccine Sales Average Price (USD/Doses) & (2021-2032) Figure 6. Global Pertussis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Whole-cell Vaccines Image Figure 10. Acellular Vaccines Image Figure 11. Global Pertussis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Pertussis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pertussis Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Pertussis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pertussis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pertussis Vaccine Sales Value Share by Type (2021-2032) Figure 17. 12 Months Below Image Figure 18. 12 Months Above Image Figure 19. Global Pertussis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Pertussis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pertussis Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Pertussis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pertussis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pertussis Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Pertussis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Pertussis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Pertussis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Pertussis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Pertussis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Pertussis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Pertussis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Pertussis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Pertussis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Pertussis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Pertussis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Pertussis Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Pertussis Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Whole-cell Vaccines
  • Acellular Vaccines
Applications
  • 12 Months Below
  • 12 Months Above
Companies covered
  • Sanofi Pasteur
  • GSK
  • Mitsubishi Tanabe Pharma
  • Wuhan Institute of Biological Products
  • Walvax Biotechnology
  • Minhai Biotechnology
  • KM Biologics
  • Chengdu Institute of Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pertussis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pertussis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pertussis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pertussis Vaccine Market Dynamics
  1. 2.1 Pertussis Vaccine Industry Trends
  2. 2.2 Pertussis Vaccine Industry Drivers
  3. 2.3 Pertussis Vaccine Industry Opportunities and Challenges
  4. 2.4 Pertussis Vaccine Industry Restraints
3 Pertussis Vaccine Market by Company
  1. 3.1 Global Pertussis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pertussis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pertussis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pertussis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pertussis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pertussis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pertussis Vaccine Company Product Type and Application
  8. 3.8 Global Pertussis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pertussis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pertussis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pertussis Vaccine Market by Type
  1. 4.1 Pertussis Vaccine Type Introduction
  2. 4.1.1 Whole-cell Vaccines
  3. 4.1.2 Acellular Vaccines
  4. 4.2 Global Pertussis Vaccine Sales Volume by Type
  5. 4.2.1 Global Pertussis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pertussis Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pertussis Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pertussis Vaccine Sales Value by Type
  9. 4.3.1 Global Pertussis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pertussis Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pertussis Vaccine Sales Value Share by Type (2021-2032)
5 Pertussis Vaccine Market by Application
  1. 5.1 Pertussis Vaccine Application Introduction
  2. 5.1.1 12 Months Below
  3. 5.1.2 12 Months Above
  4. 5.2 Global Pertussis Vaccine Sales Volume by Application
  5. 5.2.1 Global Pertussis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pertussis Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pertussis Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pertussis Vaccine Sales Value by Application
  9. 5.3.1 Global Pertussis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pertussis Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pertussis Vaccine Sales Value Share by Application (2021-2032)
6 Pertussis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pertussis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pertussis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pertussis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pertussis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pertussis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pertussis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pertussis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pertussis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pertussis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pertussis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pertussis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pertussis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pertussis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pertussis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pertussis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pertussis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pertussis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pertussis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pertussis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pertussis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pertussis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pertussis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pertussis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pertussis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pertussis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pertussis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pertussis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pertussis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pertussis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pertussis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pertussis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Pertussis Vaccine Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Pertussis Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Mitsubishi Tanabe Pharma
  14. 8.3.1 Mitsubishi Tanabe Pharma Company Information
  15. 8.3.2 Mitsubishi Tanabe Pharma Business Overview
  16. 8.3.3 Mitsubishi Tanabe Pharma Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mitsubishi Tanabe Pharma Pertussis Vaccine Product Portfolio
  18. 8.3.5 Mitsubishi Tanabe Pharma Recent Developments
  19. 8.4 Wuhan Institute of Biological Products
  20. 8.4.1 Wuhan Institute of Biological Products Company Information
  21. 8.4.2 Wuhan Institute of Biological Products Business Overview
  22. 8.4.3 Wuhan Institute of Biological Products Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Wuhan Institute of Biological Products Pertussis Vaccine Product Portfolio
  24. 8.4.5 Wuhan Institute of Biological Products Recent Developments
  25. 8.5 Walvax Biotechnology
  26. 8.5.1 Walvax Biotechnology Company Information
  27. 8.5.2 Walvax Biotechnology Business Overview
  28. 8.5.3 Walvax Biotechnology Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Walvax Biotechnology Pertussis Vaccine Product Portfolio
  30. 8.5.5 Walvax Biotechnology Recent Developments
  31. 8.6 Minhai Biotechnology
  32. 8.6.1 Minhai Biotechnology Company Information
  33. 8.6.2 Minhai Biotechnology Business Overview
  34. 8.6.3 Minhai Biotechnology Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Minhai Biotechnology Pertussis Vaccine Product Portfolio
  36. 8.6.5 Minhai Biotechnology Recent Developments
  37. 8.7 KM Biologics
  38. 8.7.1 KM Biologics Company Information
  39. 8.7.2 KM Biologics Business Overview
  40. 8.7.3 KM Biologics Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KM Biologics Pertussis Vaccine Product Portfolio
  42. 8.7.5 KM Biologics Recent Developments
  43. 8.8 Chengdu Institute of Biological Products
  44. 8.8.1 Chengdu Institute of Biological Products Company Information
  45. 8.8.2 Chengdu Institute of Biological Products Business Overview
  46. 8.8.3 Chengdu Institute of Biological Products Pertussis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chengdu Institute of Biological Products Pertussis Vaccine Product Portfolio
  48. 8.8.5 Chengdu Institute of Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pertussis Vaccine Value Chain Analysis
  2. 9.1.1 Pertussis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pertussis Vaccine Sales Mode & Process
  6. 9.2 Pertussis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pertussis Vaccine Distributors
  9. 9.2.3 Pertussis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst